×
More Charts Below
Perrigo Research and Development Expenses 2010-2024 | PRGO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Recent Trends
Perrigo research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Historical Chart (TTM)
Quarterly
Quarterly - YOY Change
Annual
Annual % Change
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$227.2B
Boston Scientific (BSX)
$140.7B
Stryker (SYK)
$132.3B
EssilorLuxottica (ESLOY)
$128.4B
Medtronic (MDT)
$105.9B
Lonza Group Ag (LZAGY)
$47.4B
Haleon (HLN)
$46.2B
ResMed (RMD)
$31.3B
Agilent Technologies (A)
$29.2B
GE HealthCare Technologies (GEHC)
$28.6B
Terumo (TRUMY)
$28.2B
Koninklijke Philips (PHG)
$22.2B
Zimmer Biomet Holdings (ZBH)
$19.4B
Insulet (PODD)
$17.3B
Baxter (BAX)
$14.8B
Smith & Nephew SNATS (SNN)
$11.4B
Sunny Optical Technology (SNPTF)
$7.6B
Lantheus Holdings (LNTH)
$6.9B
Bio-Rad Laboratories (BIO)
$6.7B
Demant (WILYY)
$6.6B
Prestige Consumer Healthcare (PBH)
$4B
Shandong Weigao Medical Polymer (SHWGF)
$3.5B
ICU Medical (ICUI)
$3.4B
Haemonetics (HAE)
$2.9B
Envista Holdings (NVST)
$2.6B
GN Store Nord (GNNDY)
$2.2B
LeMaitre Vascular (LMAT)
$1.9B
QuidelOrtho (QDEL)
$1.7B
AtriCure (ATRC)
$1.6B
Kestra Medical Technologies (KMTS)
$1.2B